Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
TRENDS Japan Pharma Earnings Show SGLT-2 Market Uptake Still Slow
May 22, 2017
-
REGULATORY Global Headquarters Watching Japan, Keep Drug Prices for Patented Period: PhRMA, EFPIA
May 19, 2017
-
REGULATORY Social Security Council Subcommittee Negative about Reference Pricing System
May 18, 2017
-
REGULATORY (Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 18, 2017
-
REGULATORY 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 17, 2017
-
REGULATORY Ninlaro, 7 Other Drugs OK’ed for Reimbursement Listing on May 24
May 17, 2017
-
BUSINESS Opdivo Ranks 2nd in FY2016 Japan Sales Ranking after Harvoni: QuintilesIMS
May 17, 2017
-
BUSINESS Aspen Japan to Expand Detailing System with Business Transfer from AZ
May 17, 2017
-
BUSINESS Suzuken Embarking on Organizational Reforms to Eliminate “High-Cost Structure,” Improve SGA Cost Ratio
May 16, 2017
-
BUSINESS Kyorin Poised to Weather Kipres Cliff with Consecutive Drug Launches: President
May 15, 2017
-
BUSINESS Sales of 4 Japan Drug Majors Dip 3.7% on Stronger Yen, Price Cuts; Global Brands Solid
May 12, 2017
-
BUSINESS Meiji Seika Pharma Forms Generic Subsidiary
May 10, 2017
-
REGULATORY LDP Confab Sees Japan Execs’ Chorus for Drug Price Maintenance during Patent Term
May 10, 2017
-
BUSINESS Sales Rep Survey - 1: Foreign Drug Makers’ Downsizing Drive Unabated
May 9, 2017
-
BUSINESS 60% of Drug Makers Increase New Grad Hires in FY2017, Otsuka Tops List: Jiho Tally
May 9, 2017
-
REGULATORY “Specified Clinical Research” Data with High Integrity Could Be Used for Drug Review: MHLW Councilor
May 8, 2017
-
REGULATORY MHLW Study Group Drafts “Items to Consider” to Promote Development of Nucleic Acid Drugs
May 2, 2017
-
REGULATORY MHLW Poised to Create Standards for Cancer Treatment in the Elderly
May 1, 2017
-
REGULATORY 2017 Economic and Fiscal Policy Guidelines Likely to Be Tinged with MOF Color
April 28, 2017
-
BUSINESS Astellas Sales Dip 4.4% on Forex Moves, Japan Biz Dented by Price Cuts
April 28, 2017
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…